Illuminare Biotechnologies Names Brian Longstreet as CEO

Illuminare Biotechnologies, a clinical-stage company pioneering novel imaging agents, has appointed Brian Longstreet as Chief Executive Officer (CEO).

The company’s previous CEO and Chairman, Walter Greenblatt, will continue as Chairman and will move into the role of Chief Financial Officer.

“On behalf of the Board of Directors, I am delighted to welcome Brian to Illuminare at this pivotal juncture in our clinical journey,” said Walter Greenblatt, Chairman of the Board of Directors. “Brian’s exceptional track record of driving strategic growth and steering novel therapies through late-stage clinical development and commercialization makes him the ideal leader to guide the Company. As we transition from an earlier-stage organization to a mature, late-stage clinical company, Brian’s strategic and commercial vision, born of deep experience, will be crucial to maximizing the value of our pipeline for shareholders and patients alike.”

Experience

Longstreet brings 30 years of pharmaceutical, biotechnology and medical technology experience, including product clinical development and global commercialization. He built his career foundation in the large pharmaceutical company environment starting with Schering-Plough and Merck & Co., and more recently has been building and growing smaller Biotech and Medtech companies including Exolvo Biosciences, ChromeX Therapeutics, CorriXR Therapeutics, and Orexigen Therapeutics. He has led teams of more than 2,000 employees and also built start-up organizations from the ground up.

“I am honored to join the talented team at Illuminare Bio at such a transformative period for the company,” said Longstreet. “I look forward to working closely with our team, the Board, and our scientific collaborators to accelerate our clinical timelines, broaden our pipeline capabilities, establish key industry partnerships, and move toward commercialization of our first product.”